SCM
CERE

Suvretta Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Suvretta Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-150,000
Closed -$1.57M – 129
2020
Q3 		$1.57M Buy
+150,000
New +$1.58M 0.03% 82

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Suvretta Capital Management's CERE Position: Q4 2020 in Review

Suvretta Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2020, closing a stake of 150,000 shares — an estimated $1.57M sold.

Suvretta Capital Management first reported a position in CERE in Q3 2020 and held it in 1 quarter. The position peaked at $1.57M in Q3 2020. 58 funds tracked by Wall St. Rank hold CERE as of Q4 2020.

  • Suvretta Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 150,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2020, an estimated $1.57M.
  • Suvretta Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Suvretta Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.57M in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2020.

Based on Suvretta Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.